A review on Zika vaccine development

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Zika virus (ZIKV), a Flavivirus, poses significant public health threats, including microcephaly in newborns and Guillain-Barré syndrome in adults.
• Transmission primarily occurs through Aedes mosquito bites, necessitating urgent development of effective countermeasures.
• The absence of specific antiviral therapies underscores the critical need for safe and potent Zika virus vaccines.

Approach:

• This review systematically analyzes five distinct ZIKV vaccine platforms: live attenuated, inactivated, nucleic acid, viral vector, and recombinant subunit vaccines.
• It evaluates the developmental progress, inherent advantages, and limitations of each vaccine type based on current clinical trial data.
• The study provides practical recommendations to guide future ZIKV vaccine research and development.

Key Points:

• Live attenuated, inactivated, nucleic acid, viral vector, and recombinant subunit vaccines are under investigation for ZIKV.
• Promising outcomes have been observed across these diverse vaccine strategies in human clinical trials.
• Each vaccine type presents a unique profile of efficacy, safety, and manufacturability.

Conclusions:

• Continued research into these five vaccine platforms is essential for combating Zika virus.
• Addressing the specific advantages and disadvantages of each approach will accelerate the development of a globally accessible ZIKV vaccine.
• Further clinical evaluation and strategic development are recommended to ensure a robust response to ZIKV outbreaks.